Clinical trials: Postreperfusion Syndrome

Liver Transplantation, Postreperfusion Syndrome

Effect of Nafamostat on Postreperfusion Syndrome (PRS)

• Completed
• Age: 18 to 70 years
• Phase 4
• Injection or infusion
• Results posted

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Trial name

NCT01001403

Testing

Nafamostat, Normal saline

Where

South Korea

Volunteers

62 people

Sponsor

Seoul National University Hospital